文献速递中毒与环境急症消化、代谢与肾脏急症

美沙酮与丁丙诺啡-纳洛酮在阿片类药物过量幸存者中的比较

Methadone vs Buprenorphine-Naloxone in Opioid Overdose Survivors.
PubMed 文献 · JAMA Netw Open · 2026-08-03
一句话结论在既往一年内有阿片类药物过量史的个体中,起始美沙酮治疗与起始丁丙诺啡-纳洛酮相比,1年内全因死亡风险降低(HR 0.78),但治疗持续时间短,且按方案分析中死亡风险无显著差异。

该回顾性队列研究采用目标试验模拟方法,纳入2017年1月1日至2023年12月31日在加拿大安大略省开始美沙酮或丁丙诺啡-纳洛酮治疗的、既往一年内因阿片类药物过量就诊于急诊科的个体,按倾向评分、性别和索引日期1:1匹配。匹配队列共5882人,美沙酮起始组1年内死亡165人(5.6%),丁丙诺啡-纳洛酮起始组死亡210人(7.1%),HR 0.78(95%CI 0.63-0.95;P=0.01),E值1.9。美沙酮组治疗中断中位时间25天(IQR 7-131),丁丙诺啡-纳洛酮组16天(IQR 5-69),HR 0.78(95%CI 0.74-0.82;P<0.001)。首次阿片类药物过量时间无显著差异(HR 1.07;95%CI 0.97-1.18;P=0.17)。按方案分析中,死亡风险无显著差异(HR 0.84;95%CI 0.48-1.47;P=0.55),美沙酮起始组阿片类药物过量风险增加(HR 1.52;95%CI 1.19-1.93;P<0.001)。作者认为,这些发现可能由未测量的混杂因素解释,需要在其他辖区进行流行病学研究来证实。

要点

  • 在既往一年内有阿片类药物过量史的个体中,起始美沙酮与起始丁丙诺啡-纳洛酮相比,1年内全因死亡风险降低:美沙酮组5.6% vs 丁丙诺啡-纳洛酮组7.1%(HR 0.78;95%CI 0.63-0.95;P=0.01)。
  • 美沙酮组治疗中断中位时间25天(IQR 7-131),丁丙诺啡-纳洛酮组16天(IQR 5-69),中断风险比为HR 0.78(95%CI 0.74-0.82;P<0.001)。
  • 两组首次阿片类药物过量时间无显著差异(HR 1.07;95%CI 0.97-1.18;P=0.17)。
  • 按方案分析中,起始美沙酮与起始丁丙诺啡-纳洛酮的死亡风险无显著差异(HR 0.84;95%CI 0.48-1.47;P=0.55),但美沙酮起始组阿片类药物过量风险增加(HR 1.52;95%CI 1.19-1.93;P<0.001)。
  • 作者认为,上述死亡风险降低可能由未测量的混杂因素解释,需要在其他辖区进行流行病学研究来证实。

适用人群与场景

  • 既往一年内因阿片类药物过量就诊于急诊科、并开始美沙酮或丁丙诺啡-纳洛酮治疗的个体;开始治疗前7天内未使用过这两种药物中的任何一种。
  • 研究地点为加拿大安大略省,治疗开始时间为2017年1月1日至2023年12月31日。

研究设计与关键结果

  • 研究设计:回顾性队列研究,采用目标试验模拟方法,纳入2017年1月1日至2023年12月31日在加拿大安大略省开始美沙酮或丁丙诺啡-纳洛酮治疗的、既往一年内因阿片类药物过量就诊于急诊科的个体,按倾向评分、性别和索引日期1:1匹配。
  • 匹配队列共5882人,平均年龄35.8岁(SD 10.8),女性1888人(32.1%)。
  • 主要终点(1年内全因死亡):美沙酮起始组165人(5.6%)死亡,丁丙诺啡-纳洛酮起始组210人(7.1%)死亡,HR 0.78(95%CI 0.63-0.95;P=0.01),E值1.9。
  • 治疗中断中位时间:美沙酮组25天(IQR 7-131),丁丙诺啡-纳洛酮组16天(IQR 5-69),HR 0.78(95%CI 0.74-0.82;P<0.001)。
  • 首次阿片类药物过量时间:两组无显著差异(HR 1.07;95%CI 0.97-1.18;P=0.17)。
  • 按方案分析:起始美沙酮与起始丁丙诺啡-纳洛酮的死亡风险无显著差异(HR 0.84;95%CI 0.48-1.47;P=0.55);美沙酮起始组阿片类药物过量风险增加(HR 1.52;95%CI 1.19-1.93;P<0.001)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(目标试验模拟)。
  • 局限:作者指出这些发现可能由未测量的混杂因素解释,需要在其他辖区进行流行病学研究来证实。

对床旁实践的改变

  • 作者认为,在既往一年内有阿片类药物过量史的个体中,起始美沙酮与起始丁丙诺啡-纳洛酮相比,与随后一年死亡风险降低相关。
  • 作者指出,治疗持续时间短,尤其是起始丁丙诺啡-纳洛酮的个体,且在接受阿片受体激动剂治疗期间死亡风险无显著差异。
  • 作者认为,上述发现可能由未测量的混杂因素解释,需要在其他辖区进行流行病学研究来证实。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Individuals who experience opioid overdoses are at high risk of death, and data are limited about the comparative effectiveness of medications for this high-risk population.

OBJECTIVE: To compare the effectiveness of methadone and buprenorphine-naloxone in individuals with a past-year history of opioid overdose.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study with target trial emulation included individuals who started methadone or buprenorphine-naloxone treatment between January 1, 2017, and December 31, 2023, in Ontario, Canada. Participants had a past-year emergency department visit for an opioid overdose and no use of either medication for 7 days. Individuals starting each medication were matched on a 1:1 basis using propensity scores, sex, and index date. Data were analyzed from November 2024 to June 2026.

MAIN OUTCOMES AND MEASURES: The primary outcome was death from any cause within 1 year, analyzed using an initiator approach with Cox proportional hazards regression. The secondary outcomes were opioid overdose and treatment discontinuation. Per-protocol analyses evaluating outcomes before medication discontinuation were also conducted.

RESULTS: A total of 5882 individuals were included in the matched cohort (mean [SD] age, 35.8 [10.8] years; 1888 female [32.1%]). In the methadone-initiating group, 165 individuals (5.6%) died within 1 year, compared with 210 (7.1%) in the buprenorphine-naloxone-initiating group (HR, 0.78; 95% CI, 0.63-0.95; P = .01), with an E-value of 1.9. Median time to treatment discontinuation was 25 days (IQR, 7-131 days) in the methadone group compared with 16 days (IQR, 5-69 days) in the buprenorphine-naloxone group (HR, 0.78; 95% CI, 0.74-0.82; P < .001). There was no significant difference in the time to first opioid overdose (HR, 1.07; 95% CI, 0.97-1.18; P = .17). In the per-protocol analyses, there was no significant difference in the hazard of death among individuals starting methadone and buprenorphine-naloxone (HR, 0.84; 95% CI, 0.48-1.47; P = .55) and an increased hazard of opioid overdose among individuals starting methadone (HR, 1.52; 95% CI, 1.19-1.93; P < .001).

CONCLUSIONS AND RELEVANCE: In this matched cohort of individuals with a past-year opioid overdose, starting methadone was associated with a reduced risk of death during the subsequent year compared with starting buprenorphine-naloxone. Treatment durations were short, particularly among individuals starting buprenorphine-naloxone, and there was no significant difference in mortality during receipt of opioid agonist treatment. These findings may be explained by unmeasured confounding, and epidemiologic studies in other jurisdictions are needed to confirm these findings.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Kleinman RA, Larney S, Sule NO, et al. Methadone vs Buprenorphine-Naloxone in Opioid Overdose Survivors. JAMA Netw Open. 2026. PMID: 42640642. doi:10.1001/jamanetworkopen.2026.29313

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。